2025-11-23 - Analysis Report
Okay, here's an analysis of Merck & Co. (MRK) based on the provided data.  The report will be in English, with key figures presented first followed by a brief analysis.

## Merck & Co. (MRK) Stock Analysis

**Ticker:** MRK
**Company Name:** Merck & Co Inc
**Description:** A global pharmaceutical company focusing on innovative medicines and vaccines.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** 15.51%
*   **VOO (S&P 500) Cumulative Return:** 94.64%
*   **Absolute Difference (MRK - VOO):** -88.7%
*   **Disparity Range:** Max: 23.9, Min: -104.3
*   **Relative Disparity:** 12.2

**Analysis:** MRK has significantly underperformed the S&P 500 based on cumulative returns. The relative disparity suggests that this underperformance is near the lower end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha    | Beta   | Cap(B) |
|------------|--------|--------|----------|--------|--------|
| 2015-2017  | 1.0%   | 68.5%  | -27.0%   | 0.2    | 134.1  |
| 2016-2018  | 36.0%  | 69.8%  | 21.0%    | 0.3    | 182.1  |
| 2017-2019  | 40.0%  | 69.8%  | 18.0%    | 0.3    | 216.8  |
| 2018-2020  | 16.0%  | 79.6%  | -8.0%    | 0.3    | 195.0  |
| 2019-2021  | 2.0%   | 79.6%  | -44.0%   | 0.7    | 191.4  |
| 2020-2022  | 15.0%  | 79.6%  | 16.0%    | 0.7    | 277.1  |
| 2021-2023  | 33.0%  | 79.6%  | 31.0%    | 0.3    | 272.3  |
| 2022-2024  | -4.0%  | 79.6%  | -25.0%   | 0.2    | 248.5  |
| 2023-2025  | -34.0% | 71.5%  | -93.0%   | 1.8    | 244.2  |

**Analysis:**

*   **CAGR:** Fluctuates significantly, showing periods of strong growth (e.g., 2017-2019) and significant decline (2023-2025).
*   **MDD:** Consistently high Maximum Drawdown indicates substantial risk and volatility.
*   **Alpha:** Periods of positive alpha (outperformance vs. benchmark) are interspersed with negative alpha (underperformance). The recent -93% alpha is concerning.
*   **Beta:** Beta values are generally low, suggesting lower sensitivity to market movements *except* for the 2023-2025 period where beta spiked to 1.8.
*   **Cap(B):**  Market capitalization has varied over time.

### 2. Recent Stock Price Movements

*   **Current Price:** $97.76
*   **Previous Close:** $94.97
*   **Change:** 2.94
*   **5-day Moving Average:** 95.41
*   **20-day Moving Average:** 89.45
*   **60-day Moving Average:** 86.02

**Analysis:**  The stock price is above all three moving averages, indicating a recent upward trend. The significant positive change ($2.94) from the previous close suggests a strong upward movement in the most recent trading session. This could be a rapid rebound.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 91.65 (Overbought)
*   **PPO:** 0.96
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (11 shares - Very Safe - MRI:0.90)
*   **Delta Previous Relative Divergence (20-day):** 5.9 (+) - Short-term Increase
*   **Expected Return (%):** -62.3%

**Analysis:**

*   **MRI:** Indicates a medium level of investment risk.
*   **RSI:**  The high RSI value indicates that the stock is currently overbought and may be due for a correction.
*   **PPO:** Positive, suggesting bullish momentum.
*   **Hybrid Signal:** Despite the overbought RSI, the hybrid signal recommends a full buy.  *This is an important point of conflict between indicators.* The "Very Safe" designation is potentially misleading given other data.
*   **Delta Previous Relative Divergence:** Confirms a recent positive trend.
*   **Expected Return:** The negative expected return suggests that, from the current price, long-term returns are expected to significantly underperform the S&P 500.

**Important Note:** The large price change from the previous close (price': 97.76, 'previousClose': 94.97, 'change': 2.94) should be carefully considered. This suggests a significant event or news impacting the stock.

### 4. Recent News & Significant Events

*   **Dividend Increase:** Merck announced an increase in its dividend to $0.85.
*   **Yield Focus:** Highlighted as a consistent moneymaker for yield-seeking investors.
*   **Mini-Tender Offer Rejection:** Merck recommends rejecting Tutanota's "mini-tender" offer.
*   **Sector Gains:** Merck's shares rose along with other companies in the sector (Mettler-Toledo, Agilent, Waters Corporation, Regeneron).
*   **Market Rally:**  Part of a broader market rally.
*   **FDA Approval:** FDA approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ in combination with Padcev® for certain bladder cancer treatments.

**Analysis:**

*   The dividend increase and positive coverage as a "moneymaker" are positive signals.
*   The FDA approval for KEYTRUDA is a significant positive catalyst, likely contributing to the recent price surge. This approval validates their pipeline and future revenue potential.
*   The mini-tender offer rejection is a standard defensive move.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 2.00 (~Buy)
*   **Opinions:** 26
*   **Target Price (avg/high/low):** 102.92 / 139.00 / 82.00
*   **Recent Rating Changes:** Not specified, marked as empty.

**Analysis:**  Analysts generally have a "Buy" rating on the stock.  The average target price ($102.92) suggests a moderate upside from the current price, while the high target ($139.00) indicates some analysts are very bullish.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-11-05 | 2.32 | 17.28 B$    |
| 2025-08-05 | 1.76 | 15.81 B$    |
| 2025-05-02 | 2.01 | 15.53 B$    |
| 2024-11-06 | 1.25 | 16.66 B$    |
| 2025-11-05 | 1.25 | 16.66 B$    |

**Analysis:**  The most recent EPS and revenue figures (2025-11-05) show a strong performance. Both EPS and revenue have generally been increasing, although there may be some seasonality.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-09-30 | $17.28B    | 77.69%        |
| 2025-06-30 | $15.81B    | 77.50%        |
| 2025-03-31 | $15.53B    | 77.98%        |
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
|------------|------------|-------|
| 2025-09-30 | $51.85B    | 11.16% |
| 2025-06-30 | $48.99B    | 9.04%  |
| 2025-03-31 | $48.34B    | 10.51% |
| 2024-12-31 | $46.31B    | 8.08%  |
| 2024-09-30 | $44.50B    | 7.09%  |

**Analysis:**

*   **Revenue:**  Generally increasing revenues.
*   **Profit Margin:** Consistently high profit margins, indicating strong profitability.
*   **Equity:** Growing equity base.
*   **ROE:** Increasing Return on Equity, demonstrating improved efficiency in generating profits from equity.

### 7. Overall Summary

Merck (MRK) has recently experienced a significant price increase, likely driven by positive news including the FDA approval of KEYTRUDA in combination with Padcev. While it has significantly underperformed the S&P 500 historically, recent earnings and financial data show strong revenue, profit margins, and ROE. Analyst opinions are generally positive ("Buy").

**Key Considerations:**

*   **Overbought Condition:** The high RSI suggests caution in the short-term as a pullback is possible.
*   **Conflicting Signals:** The Hybrid Signal recommends a buy, but the negative expected return and historical underperformance relative to the S&P 500 warrant careful consideration.
*   **FDA Approval Impact:** The long-term impact of the KEYTRUDA approval needs to be evaluated. This could be a major driver of future growth.
*   **Beta Spike:** The recent high beta suggests that MRK may be more sensitive to market fluctuations than it has been historically.

**Recommendation:**

While the recent FDA approval and positive earnings are encouraging, the historical underperformance, overbought RSI, and negative expected return suggest a cautious approach. It would be best to see if there is a pullback or correction, before investing.
